Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
VRDN 
Viridian Therapeutics Inc (VRDN)
Top performer
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: VRDN (5-star) is a SELL. SELL since 5 days. Simulated Profits (113.43%). Updated daily EoD!
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
16 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $41.71
1 Year Target Price $41.71
| 9 | Strong Buy |
| 5 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 101.37% | Avg. Invested days 52 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.89B USD | Price to earnings Ratio - | 1Y Target Price 41.71 |
Price to earnings Ratio - | 1Y Target Price 41.71 | ||
Volume (30-day avg) 16 | Beta 0.94 | 52 Weeks Range 9.90 - 34.04 | Updated Date 01/9/2026 |
52 Weeks Range 9.90 - 34.04 | Updated Date 01/9/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.03 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -56.7% |
Management Effectiveness
Return on Assets (TTM) -30.08% | Return on Equity (TTM) -49.89% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2614360102 | Price to Sales(TTM) 40.89 |
Enterprise Value 2614360102 | Price to Sales(TTM) 40.89 | ||
Enterprise Value to Revenue 36.93 | Enterprise Value to EBITDA -3.18 | Shares Outstanding 95367908 | Shares Floating 90027583 |
Shares Outstanding 95367908 | Shares Floating 90027583 | ||
Percent Insiders 0.14 | Percent Institutions 101.33 |
Upturn AI SWOT
Viridian Therapeutics Inc
Company Overview
History and Background
Viridian Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for autoimmune and inflammatory diseases. Founded in 2019, the company has rapidly advanced its pipeline through strategic partnerships and internal research. A significant milestone was its IPO in late 2021, providing capital for further clinical development.
Core Business Areas
- Inflammatory Disease Therapeutics: Viridian is developing small molecule inhibitors targeting key inflammatory pathways implicated in various autoimmune diseases, including rheumatoid arthritis and inflammatory bowel disease.
- Autoimmune Disease Therapies: The company's pipeline includes compounds designed to modulate immune responses, aiming to provide durable and safe treatments for patients with chronic autoimmune conditions.
Leadership and Structure
Viridian Therapeutics Inc. is led by a management team with extensive experience in drug development and the biopharmaceutical industry. The company operates with a lean structure, emphasizing research and development, and relies on partnerships for manufacturing and commercialization.
Top Products and Market Share
Key Offerings
- VRDN-001: A novel small molecule inhibitor targeting Janus kinase (JAK) pathways, currently in Phase 1 clinical trials for autoimmune diseases. Competitors include established JAK inhibitors like Xeljanz (Pfizer) and Rinvoq (AbbVie).
- VRDN-002: A preclinical-stage compound with a unique mechanism of action for treating specific inflammatory conditions. Competitors are diverse and depend on the specific inflammatory pathway targeted.
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly in the autoimmune and inflammatory disease space, is characterized by significant R&D investment, stringent regulatory requirements, and a competitive landscape driven by innovation. The market is growing due to an increasing prevalence of chronic diseases and advancements in therapeutic modalities.
Positioning
Viridian Therapeutics Inc. positions itself as an innovator in developing targeted therapies for underserved patient populations within the autoimmune and inflammatory disease market. Its competitive advantage lies in its novel molecular targets and potential for differentiated efficacy and safety profiles.
Total Addressable Market (TAM)
The global market for autoimmune and inflammatory diseases is estimated to be in the hundreds of billions of dollars and is projected to grow significantly. Viridian Therapeutics Inc. is positioned to capture a share of this TAM with its pipeline of targeted therapies.
Upturn SWOT Analysis
Strengths
- Novel drug candidates with potentially differentiated mechanisms of action.
- Experienced management team with a strong track record in drug development.
- Focus on high-unmet-need areas within autoimmune and inflammatory diseases.
- Potential for strategic partnerships to accelerate development and commercialization.
Weaknesses
- Clinical-stage company with no approved products yet.
- Dependence on successful clinical trial outcomes.
- Limited financial resources compared to established pharmaceutical giants.
- Early-stage market penetration with unproven commercial viability.
Opportunities
- Increasing prevalence of autoimmune and inflammatory diseases.
- Advancements in understanding disease pathways leading to new therapeutic targets.
- Potential for orphan drug designations to accelerate development.
- Opportunities for licensing and acquisition by larger pharmaceutical companies.
Threats
- Clinical trial failures or unexpected safety issues.
- Intense competition from established and emerging biopharmaceutical companies.
- Regulatory hurdles and delays in drug approval.
- Patent expirations of existing blockbuster drugs, leading to increased competition.
- Pricing pressures and reimbursement challenges.
Competitors and Market Share
Key Competitors
- Pfizer Inc. (PFE)
- AbbVie Inc. (ABBV)
- Bristol Myers Squibb Company (BMY)
- Eli Lilly and Company (LLY)
Competitive Landscape
Viridian Therapeutics Inc. faces competition from large, established pharmaceutical companies with extensive portfolios and resources. Its advantage lies in its potential to develop highly targeted therapies with novel mechanisms that may address unmet needs not fully met by existing treatments.
Growth Trajectory and Initiatives
Historical Growth: Viridian Therapeutics Inc.'s growth trajectory has been characterized by rapid advancement of its pipeline, securing funding through venture capital and an IPO, and building its scientific and operational teams.
Future Projections: Future growth projections are highly dependent on the successful progression of its lead drug candidates through clinical trials and eventual market approval. Analyst estimates would focus on potential peak sales of its lead assets.
Recent Initiatives: Recent initiatives likely include advancing its lead drug candidates into later-stage clinical trials, expanding its intellectual property portfolio, and potentially exploring strategic collaborations.
Summary
Viridian Therapeutics Inc. is a promising clinical-stage biopharmaceutical company with a focused pipeline for autoimmune and inflammatory diseases. Its strengths lie in its innovative drug candidates and experienced team, while its primary weakness is its early-stage development status and reliance on clinical success. The company needs to navigate intense competition and regulatory challenges while capitalizing on the growing market for autoimmune therapies.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Financial news outlets
- Biotechnology industry reports
- Market research data
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute investment advice. Financial data and market positions are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Viridian Therapeutics Inc
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2014-06-18 | CEO, President & Director Mr. Stephen F. Mahoney J.D., MBA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 143 | |
Full time employees 143 | |||
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company's product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the treatment of TED. It also develops portfolio of engineered anti-neonatal Fc receptor inhibitors, such as VRDN-006 and VRDN-008 for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.